English Abstract Journal Article Review Ppublish
PubMed: 40617721 DOI: 10.1016/j.bulcan.2025.06.003
[Hormone therapy in the adjuvant setting based on risk assessment].
Bull Cancer 112(7-8):771-780
Authors: Julie Cabal, Céline Lescure, Véronique Dieras, Fanny Le Du
Affiliations
- CLCC Eugène-Marquis, Rennes, France.
- CLCC Eugène-Marquis, Rennes, France.
Abstract
Hormone therapy is essential in the adjuvant management of early-stage HR+ breast cancer. Risk assessment for recurrence is a fundamental pillar in guiding therapeutic strategies and personalizing patient care. Tumors with a low risk of recurrence, eligible for treatment de-escalation, can be managed with standard hormone therapy. High-risk or intermediate-risk tumors warrant intensified approaches, including targeted therapies. This article reviews recent questions regarding the extension of hormone therapy to ovarian suppression and current strategies, with a focus on clinical studies such as OlympiA, monarchE, and NATALEE, which currently guide therapeutic decisions.
MeSH
Risk Assessment, Neoplasms, Hormones, Therapeutics